Asset Manager

Updated:

Genomic Health

Genomic Health, connected to Exact Sciences, operates globally in cancer prevention and therapy guidance. Offices across Asia, North America and Europe.

Genomic Health

Genomic Health is a global entity with offices in Shenzhen, London, Princeton, Beijing, Los Altos, Shanghai, Redwood City, Hoboken, and Wien. The firm's founding year and principal operators are not publicly disclosed, though its website aligns with Exact Sciences, a public company. Wealth origin remains opaque. The firm's strategy centers on cancer care, including prevention, early detection, and therapy guidance. Its asset-class mix is unclear, but it operates in healthcare services and digital health by offering tests such as Oncotype DX Breast Recurrence Score and Cologuard. Geographic footprint spans China, the United Kingdom, the United States, and Austria. Named portfolio companies or deals are not available from public sources. No data exists on Genomic Health's AUM, professional headcount, or deployment. The firm has additional offices in multiple countries but no mandated adjacent vehicles are confirmed. Recent activity is not verifiable due to scarce public information. An unusual structural differentiator is Genomic Health's apparent linkage to Exact Sciences, a publicly traded firm, suggesting the entity may operate as an international arm or investment vehicle for cancer diagnostics. Governance and succession details are not disclosed.

General information

Firm type

Asset Manager

Year founded

AUM

Undisclosed

Location

Region

Asia

Country

China

City

Shenzhen

Corporate office

Shenzhen, China

Additional offices

London, United Kingdom · Princeton, United States · Beijing, China · Los Altos, United States · Shanghai, China · Redwood City, United States · Hoboken, United States · Wien, Austria

Sector focus

Healthcare ServicesDigital Health

Frequently asked questions

Who runs investment decisions at Genomic Health?

Genomic Health does not publicly name its principals or investment decision-makers. The firm's leadership team is not listed on its website or other available sources.

How does Genomic Health source proprietary deal flow?

No information is available on Genomic Health's deal sourcing approach. The firm's website focuses on cancer tests and does not detail investment operations.

Is Genomic Health structured as a single family office or does it operate more like a venture firm?

Genomic Health's structure is unclear. Based on its offices and association with Exact Sciences, it may function as an international arm for cancer diagnostics rather than a direct investment entity.

Does Genomic Health participate in fund commitments or only direct deals?

Public sources do not indicate whether Genomic Health participates in fund commitments, directs deals, or engages in other investment structures.

What investment stages does Genomic Health typically target?

Genomic Health does not disclose investment stage preferences. Its focus appears operational, centered on cancer test development and distribution rather than stage-specific investing.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo